Dr. Johnson on New Drug Approvals for EGFR Exon 20 Insertion Mutation+ NSCLC

Partner | Cancer Centers | <b>Sarah Cannon</b>

Melissa L. Johnson, MD, discusses new drug approvals for EGFR exon 20 insertion mutation–positive non–small cell lung cancer.

Melissa L. Johnson, MD, program director, Lung Cancer Research, lead, Solid Tumor Immune Effector Cellular Therapy Program, Sarah Cannon Research Institute, discusses new drug approvals for EGFR exon 20 insertion mutation–positive non–small cell lung cancer (NSCLC). 

In 2021, 2 new drugs were approved in the metastatic setting for the small subgroup of patients with NSCLC harboring EGFR exon 20 insertion mutations, Johnson says. These new approvals included amivantamab-vmjw (Rybrevant), which is given intravenously with a loading dose followed by once every 2 weeks, and mobocertinib (Exkivity), which is given orally daily, Johnson explains.

Notably, these drugs have differing safety profiles and are administered differently, which makes them reasonable options for different groups of patients, Johnson continues. Overall, it is important to become familiar with the differences in the toxicity profiles of the drugs to inform optimally selecting between them for patients, Johnson concludes.